Introduction
============

Autophagy captures cytoplasmic contents, such as excess or defective proteins and organelles, for degradation by the lysosome. It is initiated in response to various stimuli, including nutritional state of the cell and environmental stresses such as starvation and hypoxia. As such, autophagy is an important process of regulating cellular homeostasis and survival. It is a well-studied process that is orchestrated by over 35 autophagy-related (ATG) proteins and can be organized into multiple steps: phagophore initiation, membrane elongation, autophagosome formation and autophagosome fusion with hydrolytic lysosomes (Figure [1A](#F1){ref-type="fig"}; [@B36]). Autophagy can be selective in terms of cargo capture via the recruitment of selective autophagy receptors. Autophagy receptors can interact with ubiquitin tags that decorate the cargo \[via its ubiquitin-binding domain (UBD)\], and with LC3 proteins of nascent autophagosomes \[via its LC3-interacting region (LIR) motif\] ([@B56]). Some autophagy receptors, particularly p62/SQSTM1 and optineurin, are regulated by Tank-binding kinase 1 (TBK1)-mediated phosphorylation, and are key players in the autophagic degradation of invasive pathogens ([@B62]; [@B48]; [@B55]).

![**(A)** Autophagy is a regulated multi-step process that leads to cargo degradation. Autophagy can eliminate cargo such as virus and viral-derived antigens. It can be organized into 5 distinct steps beginning with (1) the initiation of phagophore formation which (2) nucleates around the intended cargo. The cargo can be selectively recruited by autophagy receptors such as p62, which can be regulated by TBK1. (3) The phagophore elongates and completes to form a structure termed autophagosome which then (4) fuses with nearby lysosomes carrying hydrolytic enzymes. This eventually leads to (5) the acidification and hence degradation of the contained cargo. **(B)** Autophagy plays an antiviral role in various human infections by modulating different aspects of the immune response. Autophagy facilitates viral clearance by recruiting selective autophagy receptors p62 and SMURF1 to target viral components to autophagosomes for lysosomal degradation. Reported targets include HSV-1, HIV-1 Tat protein, and the capsids of CHIKV and SV. Disruption of the targeting of viral proteins, such as CHIKV and SV capsids, may lead to their toxic accumulation and cause cell death. Autophagy also promotes pathogen recognition by aiding delivery of viral PAMPs, e.g., HIV-1 and IAV RNA genomes to cognate TLRs in endosomes, which results in enhanced production of antiviral cytokines. On the other hand, autophagy can prevent excessive inflammation by negatively regulating signaling pathways through Atg9a or Beclin-1, or by clearing mitochondria that are producing inflammatory-inducing signals such as reactive oxygen species (ROS). Autophagy supports amplification of inflammatory responses by regulating adaptive immune responses, through the processing and presentation of viral antigens, such as EBV EBNA1, IAV MP1, HIV-1/SIV gag and HSV-1 glycoprotein B, on MHC class I or II to T cells. Autophagy can also be induced in distant cells, i.e., in paracrine manner, which may confer protection to these cells as seen with multiple viral infections including CVB, HCV, and HSV-1.](fcell-06-00155-g001){#F1}

Autophagy plays a key role in cellular immunity to human infections ([@B50]; [@B44]). In the case of human viral infections, autophagy can be either proviral or antiviral ([@B25]; [@B14]). Some viruses highjack the autophagy machinery for their intracellular survival, while others express specific proteins to evade autophagy and propagate in host cells. Antiviral autophagy can (1) selectively target pathogens for degradation, (2) promote pathogen recognition and inflammatory cytokine responses, (3) regulate inflammation, (4) control cell survival, (5) promote antigen presentation and/or (6) be regulated in a paracrine-mediated fashion, a departure from the classic cell autonomous route (Figure [1B](#F1){ref-type="fig"}; [@B24]; [@B25]; [@B14]; [@B44]). By focusing on these themes of antiviral autophagy, this review will highlight the protective nature of autophagy. We will draw from examples of human viral infections representing significant disease burden, whose interplay with autophagy has been supported by experimental and/or clinical evidence.

Pathogen or Viral Antigen Clearance by Autophagy
================================================

Selective autophagy has been reported to control several human viral infections *in vitro*, leading to the clearance of pathogens or viral antigens and host cell survival. One of the first viruses shown to engage the autophagy machinery was Sindbis virus (SV), a positive-stranded RNA alphavirus that typically causes mild disease in humans. Autophagy receptors p62 and SMURF1 were found to target SV capsid, in a ubiquitin-independent manner, to autophagosomes in human HeLa cells and mouse embryonic fibroblasts (MEFs) ([@B41], [@B42]). Depletion of p62 in HeLa cells or *Atg5* in mouse neurons *in vivo* led to an accumulation of toxic SV capsid and higher virus-induced mortality, without altering SV replication ([@B41]). Whether SV can express proteins to counteract autophagy is not yet known.

Similar to SV, p62 is involved in targeting toxic Chikungunya virus (CHIKV) capsid to autophagosomes in HeLa cells, but in a ubiquitin-dependent manner ([@B17]). CHIKV, also a positive-stranded RNA alphavirus, is a mosquito-borne virus causing severe pathologies in humans that range from febrile arthralgia, rash to encephalopathy ([@B6]). siRNA-mediated depletion of p62 led to an increase in both cell mortality and CHIKV replication, while p62 overexpression promoted cell viability in CHIKV-infected cells ([@B17]). In contrast, another autophagy receptor NDP52 was shown to have a proviral role although overall autophagy played a cytoprotective role in CHIKV infection ([@B17]).

Human immunodeficiency virus-1 (HIV-1), a lentivirus that is transmitted sexually through infected body fluids, is targeted by autophagy in human CD4^+^ T cells *in vitro* ([@B52]). HIV-1 primarily infects CD4^+^ T cells, consequently compromising the individual's immune defense and leading to acquired immunodeficiency syndrome (AIDS) ([@B34]). HIV-1 integrates its DNA into the host's genome, and recruits its transactivator protein Tat to activate viral transcription. Tat protein is therefore essential for HIV-1 replication. However, Tat protein is targeted by p62 in HEK293T cells, which directs it to autophagosomes in a ubiquitin-independent manner ([@B52]). Consistent with this, depleting p62 in HEK293T cells resulted in accumulation of Tat protein, and enhancing autophagy in a chronically HIV-1-infected T cell line led to reduction of Tat protein levels ([@B52]). Furthermore, peripheral blood mononuclear cells (PBMCs) from HIV-1-infected non-progressor individuals showed higher number of HIV-1 particle-containing autophagic vesicles compared with HIV-1-infected normal progressors, suggesting a role for autophagy in limiting the pathogenesis of HIV-1 *in vivo* ([@B39]). However, HIV-1 can modulate autophagy and expresses multiple autophagy inhibitors, such as Vif, Nef, and Env, which operate in a cell type-specific manner ([@B29]). Hence, autophagy can be viewed to control HIV-1 replication by targeting viral components to degradation in specific cell types.

Herpes simplex virus-1 (HSV-1) is a ubiquitous, neurotropic α-herpesvirus with a global seroprevalence of 67% ([@B30]). It typically manifests as benign, self-limiting mucocutaneous ulcers, but in rare cases may cause life-threatening herpes simplex encephalitis (HSE) ([@B61]). Reports have identified HSV-1-encoded ICP34.5 and Us11 as autophagy inhibitors, which exert their effects by targeting Beclin-1 and protein kinase R (PKR), respectively ([@B40]; [@B33]). Studies in primary MEFs and mice described increased autophagy following infection with ICP34.5-deficient HSV-1, as suggested by an increased number of autophagosomes and virions in neuronal autophagosomes, respectively ([@B58]; [@B2]). During HSV-1 infection, autophagy appears to be operating in a cell type-specific manner ([@B64]). For example, in contrast to mitotic cells such as MEFs and mouse keratinocytes, post-mitotic mouse primary neuronal cells predominantly use autophagy over interferon (IFN) as a viral control mechanism ([@B64]). In MEFs, HSV-1 was shown to be selectively targeted by p62 and SMURF1. HSV-1-infected *smurf1−/−* MEFs failed to target HSV-1 virions to autolysosomes, resulting in more HSV-1 virions in autophagosomes ([@B42]). In mouse primary trigeminal neurons *in vitro*, HSV-1 infection triggered the formation of p62-mediated autophagosomes ([@B18]). Finally, infection of HEK293T cells with ICP34.5-deficient HSV-1 led to the recruitment of TBK1- and p62-mediated autophagy, and viral restriction ([@B55]). However, the exact viral target of p62 and SMURF1, and the role of ubiquitin in mediating receptor-virus interactions, is not yet known. Reports using human HFFF2 fibroblasts and mouse dendritic cells (DCs) have shown that autophagy is triggered by HSV-1 double-stranded DNA (dsDNA), and is independent of viral replication but dependent on STING ([@B35]; [@B51]).

Autophagy and Cellular Immunity: Pathogen Recognition and Cytokine Responses
============================================================================

Cellular immunity requires the detection of viral pathogen-associated molecular patterns (PAMPs) by their cognate receptors to produce antiviral cytokines, such as type-I IFNs ([@B13]). Autophagy can deliver viral PAMPs to their receptors, and help amplify the production of inflammatory cytokines. The capacity of autophagy to facilitate viral recognition and modulate downstream cytokine production has been demonstrated in the case of HIV-1 infections. During HIV-1 infection in human primary plasmacytoid DCs, autophagy plays a key role in presenting the HIV-1 RNA genome to its cognate immune receptor Toll-like receptor-7 (TLR7) in endosomes, leading to the induction of IFNα ([@B22]; [@B65]). Silencing the expression of ATG7 in plasmacytoid DCs *in vitro* leads to a significant decrease in IFNα production following HIV-1 infection, highlighting a crucial role for autophagy in mediating TLR7-IFN signaling ([@B65]).

Autophagy also plays an important role in mediating cytokine production during infection by influenza A virus (IAV). IAV, an RNA virus, is a pandemic threat and global health concern. It targets epithelial cells of the respiratory tract, and in severe cases may cause pneumonia or pulmonary damage ([@B45]). In the case of infection with highly virulent IAV strains H1N1 and H5N1, high morbidity has been attributed to excessive host-induced inflammatory cytokine production ([@B46]). IAV infection was shown to induce autophagy in primary human blood macrophages, which regulates the production of CXCL10 and IFNα. When these cells were depleted of ATG5 or treated with the autophagy inhibitor 3-methyladenine (3-MA), they produced lower CXCL10 and/or IFNα levels ([@B20]). The precise mechanism by which autophagy facilitates this aspect of IAV infection in human blood macrophages is unknown, but is thought to involve recognition of viral RNA by endosomal TLR3 ([@B20]). In contrast, IAV-induced autophagy in MEFs can prevent IFNβ production, and enhance viral replication ([@B47]). The induction of autophagy during IAV infection is complex: it is initially cytoprotective but is later counteracted by the IAV matrix protein 2 (M2) which targets Beclin-1 to block lysosomal fusion with autophagosomes ([@B11]). Taken together, these data suggest an immunopathological role of autophagy in controlling cytokine production and IAV infection, in potentially a tissue-specific manner.

From the examples of HIV-1 and IAV, autophagy plays a fundamental role in modulating the primary antiviral response, by promoting viral recognition through TLR-dependent signaling and inflammatory cytokine production.

Anti-Inflammatory Actions of Autophagy
======================================

In addition to promoting inflammation, autophagy is crucial for preventing prolonged and excessive inflammation detrimental to the host. Components of the autophagy machinery, such as Beclin-1 and Atg9a, interact with the cytoplasmic type-I-IFN-inducing STING-TBK1 pathway. A study found that Beclin-1 interacts with dsDNA sensor cGAS to dampen IFNβ production in HEK293T cells stimulated with dsDNA or infected with HSV-1 ([@B26]). This interaction also leads to clearance of dsDNA through autophagy, limiting the otherwise persistent IFNβ-mediated inflammation ([@B26]). The depletion of Beclin-1 was shown to increase cGAS-mediated IFNβ production while reducing HSV-1 replication in RAW264.7 mouse macrophages ([@B26]). In MEFs stimulated with dsDNA, Atg9a had a similar role and negatively regulated the STING-TBK1-IFN pathway by binding to STING and preventing its assembly with TBK1 in LC3-positive structures ([@B53]). *Atg9a*-knockout mice revealed an increase in IRF3 phosphorylation and IFNβ production following dsDNA stimulation ([@B53]). However, whether HSV-1 infection (or infection of other dsDNA viruses) is subject to Atg9a-mediated regulation remains unknown.

Autophagy may also negatively regulate inflammation indirectly by clearing host DAMPs, such as reactive oxygen species (ROS) released by mitochondria. This has been observed in mice BMDCs where IAV genomic RNA is detected by the NOD2-RIPK2 pathway, which activates ULK1 to induce RIPK2-mediated autophagic clearance of damaged mitochondria ([@B32]). In RIPK2-deficient mice BMDCs infected with IAV, mitochondria accumulated in cells resulting in elevated production of superoxide. This led to the hyperactivation of the NLRP3 inflammasome and an increased secretion of the inflammatory cytokine interleukin (IL)-18 ([@B32]). A similar observation was made in *Atg5*-deficient MEFs and mouse primary macrophages stimulated with dsRNA analog poly(I:C), which led to excessive RIG-I-like-receptor signaling ([@B57]). Furthermore, ectopic P-granules autophagy protein 5 homolog (EPG5; a protein that regulates autolysosomal formation) has been shown to control pulmonary inflammation. Lung macrophages from *Epg5−/−* mice showed excessive production of inflammatory IL-1β and IL-13 cytokines, resulting in resistance to IAV infection ([@B31]).

These reports highlight the important role of autophagy in attenuating inflammation. The autophagy machinery can limit inflammation by regulating cytosolic NLR- and STING-mediated signaling pathways through disposal of their ligands, inactivation of their cognate receptors or interaction with their downstream effector molecules.

Autophagy and Cell Survival
===========================

As shown from investigations of multiple human viral infections, autophagy plays a role in promoting cell survival and limiting pathogenesis. This has been demonstrated by the ability of mouse L cell mutant gro29 cells which have high basal autophagy to restrict HSV-1 replication ([@B21]). In contrast, Atg16L^HM^ mice, which have reduced basal autophagy, showed high mortality following infection with CHIKV *in vivo* ([@B16]). One mechanism by which autophagy may promote cell survival during viral infection is by degrading and preventing accumulation of toxic viral proteins, such as viral capsids, in the infected cells. This has been demonstrated in the case of CHIKV and SV infected cells, as discussed above ([@B41]; [@B17]). Furthermore, reports have documented the cytoprotective effect of autophagy-enhancing drugs, such as vitamin D, MG132 and rapamycin, in viral infections. For example, primary human macrophages have shown benefit from vitamin D treatment, which limits HIV-1 replication *in vitro* ([@B5]). Treating HSV-1-infected human corneal epithelial (HCE) cells with MG132 can reduce viral titres ([@B63]). Moreover, pre-conditioning human fibroblasts *in vitro* with rapamycin has been shown to promote cell survival following HSV-1 infection ([@B1]). This cytoprotective role for autophagy that occurs early in HSV-1 infection appears to be a TBK1-dependent process ([@B1]). In agreement with this, TBK1 deficiencies render human fibroblasts susceptible to HSV-1 infection and leads to increased cell mortality ([@B12]). These data support literature showing that TBK1 is a key player in protective autophagy against bacterial infections ([@B60]), and extend its protective role to viral infection.

Autophagy and Adaptive Immunity: Antigen Presentation
=====================================================

Through its degradative function, autophagy is particularly useful for generating endogenous peptide antigens for major histocompatibility complex (MHC)-II presentation ([@B8]; [@B44]). In viral infections, autophagy generates viral antigens loaded onto MHC-I and MHC-II for presentation to T cells ([@B38]). Epstein-Barr virus (EBV) is an oncogenic γ-herpesvirus causing a spectrum of human diseases ranging from mononucleosis to lymphomas and carcinomas ([@B59]). Historically, EBV nuclear antigen 1 (EBNA1) was one of the first viral antigens shown to be processed by autophagy and loaded on MHC-II molecules of EBV-transformed B cell lines ([@B43]). Inhibition of autophagy leads to accumulation of EBNA1 in autophagosomes of EBV-transformed lymphoblastoid cell lines, and a decrease in EBNA1-specific CD4^+^ T cell recognition via MHC-II ([@B43]).

As a result of reduced MHC-II antigen presentation, mice with *Atg5*-deficient DCs intradermally injected with HSV-1 showed significantly lower IFNγ production by CD4^+^ T cells ([@B23]). In addition, autophagy can deliver viral antigens for MHC-I cross-presentation. Using a mouse BMA3.1A7 macrophage cell line for CD8^+^ cell stimulation, HSV-1 glycoprotein B (gB) was presented on MHC-I in an autophagy-dependent manner ([@B9]; [@B49]).

Autophagy is also vital for efficient stimulation of antiviral CD4^+^ T cells in HIV-1/Simian immunodeficiency virus (SIV) and IAV infections. Knocking down LC3 protein or inhibiting autophagy using 3-MA in human DCs led to reduced antigen processing and MHC-II presentation, and a decrease in HIV-1-specific CD4^+^ T cell response ([@B4]). On the other hand, enhancing autophagy in human DCs with rapamycin resulted in a more pronounced HIV-1-specific CD4^+^ T cell response ([@B4]). Fusing SIV gag protein to LC3 in mice BMDCs was also shown to improve antigen-specific CD4^+^ T cell responses *in vitro* ([@B15]). Similar results were obtained *in vivo* where immunizing mice with SIV gag-LC3 resulted in a stronger humoral immune response, with CD4^+^ T cells producing higher levels of IFNγ, TNFα and IL-2 ([@B15]). Conjugating IAV matrix protein 1 (M1) to LC3 in HaCat human epithelial cells, B cells and DCs led to enhanced antigen-specific human CD4^+^ T cell responses *in vitro*, as measured by IFNγ ([@B54]).

Taken together, autophagy can perpetuate the initial response to viral infection by priming and mediating T cell responses of the adaptive immune system to ensure effective viral clearance.

Beyond Cell Autonomous Immunity: Paracrine Regulation of Autophagy
==================================================================

Since its discovery, the primary focus of autophagy research has been to investigate its role on a cell autonomous level. Interestingly, two recent reports have demonstrated that autophagy can also be triggered at a cell population level (i.e., in a paracrine manner) to affect distant cells. A first report showed that autophagy could be triggered in distant and distinct cell types that can protect them from a variety of viral infections ([@B7]). In this case, primary human placental trophoblasts can protect other cells from coxsackievirus B3 (CVB), hepatitis C virus (HCV), vesicular stomatitis virus (VSV) and vaccinia virus (VACV), by secreting signals that induce autophagy to resist infections. This concept is particularly relevant in the womb, allowing maternal trophoblasts to confer resistance to viral infections to the growing fetus.

A second report described the paracrine regulation of autophagy early in HSV-1 infection ([@B1]). In this case, HSV-1 infection of human fibroblasts was shown to induce autophagy in cells neighboring an infection site. Despite having functional basal autophagy, HSE patient-derived fibroblasts deficient in TBK1 specifically failed to mount paracrine-mediated autophagy during HSV-1 infection. The study further showed that autophagy induction early during infection may protect cells from death. The autophagic role of TBK1 has previously been associated with inflammation control in neurodegenerative amyotrophic lateral sclerosis (ALS) ([@B10]). These observations highlight a potential involvement of TBK1 in controlling neuroinflammation through autophagy in HSE.

Conclusion
==========

Many open questions remain concerning the precise role of autophagy in human viral infections. Studies looking at human responses *in vivo* are rare, due to difficulty of conducting these studies. However, a wealth of studies using animal *in vitro/ex vivo/in vivo* and human *in vitro/ex vivo* models have given remarkable insights into the role of autophagy in disease manifestation.

In this review, we discuss human viruses modulated by autophagy that represent a significant clinical burden. We highlight how autophagy is protective and may be used to enhance current treatment options (Table [1](#T1){ref-type="table"}; [@B61]; [@B37]; [@B34]; [@B6]). Several reports have shown the protective role of p62-mediated selective autophagy in various human pathogens (e.g., CHIKV, HIV-1, and HSV-1), making p62 an attractive therapeutic target. Enhancement of autophagy through p62 may provide an important therapeutic avenue for treatment of human viral diseases (Table [1](#T1){ref-type="table"}). However, p62 also participates in other biological processes, such as cell proliferation and ubiquitin-proteasomal degradation ([@B28]), and research focusing on employing p62 for therapeutic benefit should be aware of potential pleiotropic effects. The ability of p62 to interact with viruses independent of its conventional ubiquitin-binding domain also warrants further investigation. As shown in the case of HSV-1 and HIV-1 infections, augmenting autophagy using stimulants (such as rapamycin and vitamin D) can be beneficial to restrict viral replication and/or promote cell survival. Enhancing autophagy in vaccine therapies has also been beneficial, taking advantage of the role of autophagy in antigen priming. Promising results were observed in the case of IAV and HIV-1/SIV-1 infections, whereby increasing the autophagic targeting of viral protein gave rise to a heightened adaptive immune response ([@B54]; [@B15]). Moreover, autophagy is important for both MHC-I and/or -II antigen presentation in HSV-1 and HIV-1 infections, as well as for regulating inflammation by facilitating antiviral inflammatory cytokine production. Autophagy's role in fine-tuning inflammation is also important during IAV infection, where it promotes inflammatory cytokine production and prevents excessive inflammatory responses. In addition to the effects on acute disease outcome, modulating autophagy may have a promising role in the prevention or treatment of various viral post-infectious inflammation/autoimmune disorders for which there are limited treatment options (Table [1](#T1){ref-type="table"}; [@B19]; [@B3]; [@B6]; [@B27]). Harnessing autophagy's inflammation-reducing capacity can potentially prevent the development of these states, or help to resolve the inflammatory symptoms.

###### 

Opportunities for autophagy-modifying therapeutic intervention in human viral diseases.

  Virus   Available treatment for acute disease          Vaccine   Post-infectious inflammation/autoimmunity
  ------- ---------------------------------------------- --------- ---------------------------------------------------------
  CHIKV   None                                           No        Rheumatic inflammation
  HIV-1   Antiretroviral therapy (ART)                   No        HIV-associated neuroinflammation
  HSV-1   Nucleoside analog (e.g., acyclovir)            No        Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis
  IAV     Neuraminidase inhibitors (e.g., oseltamivir)   Yes       Acute infection-induced cytokine storm

Current research on autophagy is mostly focused on its role in cell autonomous immunity ([@B50]). However, recent studies have revealed a novel type of autophagy triggered in a paracrine manner in response to viral infections. Elucidating the role of paracrine-regulated autophagy may prove to be highly relevant in disease pathogenesis *in vivo*, and may be useful as a method of clinical intervention. It is tempting to speculate that similar mechanisms could also be extended to viral pathogenesis that disseminates to sensitive tissues, such as the central nervous system (CNS).

In conclusion, we have discussed here the protective nature of autophagy in light of important human viral infections, and highlighted potential therapeutic strategies that can be pursued through autophagy modulation. Most viral infections result in complex host-pathogen interplay, and therefore routes of intervention require careful consideration in terms of application. For example, certain studies of autophagy in HSV-1 infections have shown viral restriction whilst others have only demonstrated cytoprotective effects despite the presence of viral autophagy inhibitors, which may be partly due to cell type specificity. These studies reveal the intimate interactions of the virus and the host cell which will require further dissection if we wish to target the appropriate molecular pathways for antiviral therapies.
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